Here, we detail our findings that cetuximab treatment causes patient-derived CAFs isolated from three human CRC tumors to increase the secretion of EGF, which subsequently leads to increased resistance of CRC cancer cells to treatment. The gene discussed is EGF; the disease is cancer.